CoLAB AccelBio has secured its first European-funded project by joining IMPACT through the Hop-On mechanism.
IMPACT is an EIC Pathfinder initiative with an ambitious goal: to pave the way for novel therapies for major cardiovascular diseases, by implementing an AI-based integration of clinical and multi-omics data from patients with arrhythmogenic cardiomyopathy (ACM).
ACM is a genetic condition associated with ventricular arrhythmias and sudden cardiac death, particularly in young people and athletes. As no effective disease-modifying treatments are currently available, IMPACT aims to strengthen the understanding of genotype–phenotype relationships by combining large-scale patient -omics with structural and functional data from in vitro and in vivo models.
Interested in collaborating on ACM-focused translational research? Get in touch with our team.
